MedTrace Logo

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-04-20

Study results available
· View outcomes & findings →

Summary

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.

Conditions

  • Healthy

Interventions

DRUG

Ciraparantag

Ciraparantag: 180 mg, intravenous

DRUG

Placebo

Placebo: 0.9% sodium chloride, intravenous

DEVICE

Point-of-Care Coagulometer (investigational device)

Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.

Sponsors & Collaborators

  • Ciraparantag Holdings GmbH

    collaborator UNKNOWN

  • AMAG Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Advisor · Apollo Investment Management

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-13
Primary Completion
2023-08-26
Completion
2023-08-26
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04593784 on ClinicalTrials.gov